ZA200201087B - Benzoylpyridazines. - Google Patents

Benzoylpyridazines. Download PDF

Info

Publication number: ZA200201087B
Authority: ZA; South Africa
Prior art keywords: formula; compounds; solvates; acceptable salts; physiologically acceptable
Prior art date: 1999-07-10

Application number

ZA200201087A

Other languages

English (en)

Inventor

Rochus Jonas

Michael Wolf

Norbert Beier

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-10

Filing date

2002-02-07

Publication date

2003-07-30

2002-02-07 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2003-07-30 Publication of ZA200201087B publication Critical patent/ZA200201087B/en

Links

VDWSVBMVZLRATD-UHFFFAOYSA-N phenyl(pyridazin-3-yl)methanone Chemical class C=1C=CN=NC=1C(=O)C1=CC=CC=C1 VDWSVBMVZLRATD-UHFFFAOYSA-N 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 49
125000004432 carbon atom Chemical group C* 0.000 claims description 32
125000000217 alkyl group Chemical group 0.000 claims description 19
150000003839 salts Chemical class 0.000 claims description 19
239000012453 solvate Substances 0.000 claims description 19
238000000034 method Methods 0.000 claims description 17
229910052801 chlorine Inorganic materials 0.000 claims description 14
239000000126 substance Substances 0.000 claims description 13
229910052794 bromium Inorganic materials 0.000 claims description 11
125000000753 cycloalkyl group Chemical group 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 8
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
229910052731 fluorine Inorganic materials 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
206010006895 Cachexia Diseases 0.000 claims description 6
238000006243 chemical reaction Methods 0.000 claims description 6
208000023275 Autoimmune disease Diseases 0.000 claims description 5
229910052740 iodine Inorganic materials 0.000 claims description 5
201000006417 multiple sclerosis Diseases 0.000 claims description 5
206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
208000011231 Crohn disease Diseases 0.000 claims description 4
206010040047 Sepsis Diseases 0.000 claims description 4
206010052779 Transplant rejections Diseases 0.000 claims description 4
208000026935 allergic disease Diseases 0.000 claims description 4
208000006673 asthma Diseases 0.000 claims description 4
206010012601 diabetes mellitus Diseases 0.000 claims description 4
208000027866 inflammatory disease Diseases 0.000 claims description 4
206010009900 Colitis ulcerative Diseases 0.000 claims description 3
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 3
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 3
201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
125000003342 alkenyl group Chemical group 0.000 claims description 3
125000001309 chloro group Chemical group Cl* 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
150000007514 bases Chemical class 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims description 2
239000000203 mixture Substances 0.000 claims 11
208000030507 AIDS Diseases 0.000 claims 3
201000001320 Atherosclerosis Diseases 0.000 claims 3
206010006458 Bronchitis chronic Diseases 0.000 claims 3
208000026139 Memory disease Diseases 0.000 claims 3
206010027476 Metastases Diseases 0.000 claims 3
206010028980 Neoplasm Diseases 0.000 claims 3
208000001132 Osteoporosis Diseases 0.000 claims 3
201000004681 Psoriasis Diseases 0.000 claims 3
206010006451 bronchitis Diseases 0.000 claims 3
208000007451 chronic bronchitis Diseases 0.000 claims 3
208000017520 skin disease Diseases 0.000 claims 3
230000004614 tumor growth Effects 0.000 claims 3
206010012438 Dermatitis atopic Diseases 0.000 claims 2
201000008937 atopic dermatitis Diseases 0.000 claims 2
201000010099 disease Diseases 0.000 claims 2
230000002401 inhibitory effect Effects 0.000 claims 2
239000000825 pharmaceutical preparation Substances 0.000 claims 2
201000004624 Dermatitis Diseases 0.000 claims 1
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
208000025865 Ulcer Diseases 0.000 claims 1
206010009887 colitis Diseases 0.000 claims 1
239000007788 liquid Substances 0.000 claims 1
239000000546 pharmaceutical excipient Substances 0.000 claims 1
239000007787 solid Substances 0.000 claims 1
-1 n- pentyl Chemical group 0.000 description 40
239000000460 chlorine Substances 0.000 description 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
125000000000 cycloalkoxy group Chemical group 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
102000018594 Tumour necrosis factor Human genes 0.000 description 3
108050007852 Tumour necrosis factor Proteins 0.000 description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
125000006043 5-hexenyl group Chemical group 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
101100113485 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) chs-3 gene Proteins 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
230000003269 anti-cachectic effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
125000006310 cycloalkyl amino group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000006612 decyloxy group Chemical group 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
MKZRYHJQHATKLV-UHFFFAOYSA-N diazinan-1-yl(phenyl)methanone Chemical class C=1C=CC=CC=1C(=O)N1CCCCN1 MKZRYHJQHATKLV-UHFFFAOYSA-N 0.000 description 1
125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
239000003446 ligand Substances 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001599 osteoclastic effect Effects 0.000 description 1
230000002642 osteogeneic effect Effects 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
102000003998 progesterone receptors Human genes 0.000 description 1
108090000468 progesterone receptors Proteins 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Virology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)

ZA200201087A 1999-07-10 2002-02-07 Benzoylpyridazines. ZA200201087B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19932315A DE19932315A1 (de)	1999-07-10	1999-07-10	Benzoylpyridazine

Publications (1)

Publication Number	Publication Date
ZA200201087B true ZA200201087B (en)	2003-07-30

Family

ID=7914352

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200201087A ZA200201087B (en)	1999-07-10	2002-02-07	Benzoylpyridazines.

Country Status (24)

Country	Link
US (1)	US6696446B1 (pl)
EP (1)	EP1194411B1 (pl)
JP (1)	JP2003504358A (pl)
KR (1)	KR20020019923A (pl)
CN (1)	CN1146545C (pl)
AR (1)	AR024672A1 (pl)
AT (1)	ATE269311T1 (pl)
AU (1)	AU763005B2 (pl)
BR (1)	BR0012328A (pl)
CA (1)	CA2378595A1 (pl)
CZ (1)	CZ200212A3 (pl)
DE (2)	DE19932315A1 (pl)
DK (1)	DK1194411T3 (pl)
ES (1)	ES2220513T3 (pl)
HK (1)	HK1048116A1 (pl)
HU (1)	HUP0201828A3 (pl)
MX (1)	MXPA02000317A (pl)
NO (1)	NO20020096D0 (pl)
PL (1)	PL353175A1 (pl)
PT (1)	PT1194411E (pl)
SI (1)	SI1194411T1 (pl)
SK (1)	SK72002A3 (pl)
WO (1)	WO2001004099A1 (pl)
ZA (1)	ZA200201087B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050070529A1 (en) *	2001-02-12	2005-03-31	Merk Pantent Gmbh	Use of type 4 phosphodiesterase inhibitors in myocardial diseases
EP1463509A1 (en) *	2001-10-31	2004-10-06	MERCK PATENT GmbH	Type 4 phosphodiesterase inhibitors and uses thereof
HUP0401747A3 (en)	2001-11-05	2005-06-28	Merck Patent Gmbh	Piridazine derivatives of hydrazono-malonitriles, their use, process for preparation of the compounds and pharmaceutical compositions containing the compounds
US9389796B1 (en)	2015-02-23	2016-07-12	International Business Machines Corporation	Efficient register preservation on processors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3704879A1 (de)	1987-02-17	1988-08-25	Merck Patent Gmbh	Pyridazinonderivate
DE19632549A1 (de)	1996-08-13	1998-02-19	Merck Patent Gmbh	Arylalkanoylpyridazine
DE19826841A1 (de) *	1998-06-16	1999-12-23	Merck Patent Gmbh	Arylalkanoylpyridazine

1999
- 1999-07-10 DE DE19932315A patent/DE19932315A1/de not_active Withdrawn
2000
- 2000-06-27 WO PCT/EP2000/005933 patent/WO2001004099A1/de not_active Ceased
- 2000-06-27 AT AT00954422T patent/ATE269311T1/de not_active IP Right Cessation
- 2000-06-27 DE DE50006829T patent/DE50006829D1/de not_active Expired - Fee Related
- 2000-06-27 PL PL00353175A patent/PL353175A1/pl unknown
- 2000-06-27 HU HU0201828A patent/HUP0201828A3/hu unknown
- 2000-06-27 KR KR1020017015566A patent/KR20020019923A/ko not_active Ceased
- 2000-06-27 BR BRPI0012328-5A patent/BR0012328A/pt not_active IP Right Cessation
- 2000-06-27 CA CA002378595A patent/CA2378595A1/en not_active Abandoned
- 2000-06-27 PT PT00954422T patent/PT1194411E/pt unknown
- 2000-06-27 EP EP00954422A patent/EP1194411B1/de not_active Expired - Lifetime
- 2000-06-27 HK HK03100260.0A patent/HK1048116A1/zh unknown
- 2000-06-27 CN CNB008100306A patent/CN1146545C/zh not_active Expired - Fee Related
- 2000-06-27 AU AU66883/00A patent/AU763005B2/en not_active Ceased
- 2000-06-27 ES ES00954422T patent/ES2220513T3/es not_active Expired - Lifetime
- 2000-06-27 MX MXPA02000317A patent/MXPA02000317A/es active IP Right Grant
- 2000-06-27 CZ CZ200212A patent/CZ200212A3/cs unknown
- 2000-06-27 JP JP2001509710A patent/JP2003504358A/ja active Pending
- 2000-06-27 DK DK00954422T patent/DK1194411T3/da active
- 2000-06-27 US US10/030,477 patent/US6696446B1/en not_active Expired - Fee Related
- 2000-06-27 SI SI200030426T patent/SI1194411T1/xx unknown
- 2000-06-27 SK SK7-2002A patent/SK72002A3/sk unknown
- 2000-07-07 AR ARP000103466A patent/AR024672A1/es not_active Application Discontinuation
2002
- 2002-01-09 NO NO20020096A patent/NO20020096D0/no not_active Application Discontinuation
- 2002-02-07 ZA ZA200201087A patent/ZA200201087B/en unknown

Also Published As

Publication number	Publication date
DE19932315A1 (de)	2001-01-11
CN1146545C (zh)	2004-04-21
ES2220513T3 (es)	2004-12-16
MXPA02000317A (es)	2002-07-30
EP1194411B1 (de)	2004-06-16
DE50006829D1 (de)	2004-07-22
NO20020096L (no)	2002-01-09
AR024672A1 (es)	2002-10-23
WO2001004099A1 (de)	2001-01-18
PT1194411E (pt)	2004-11-30
JP2003504358A (ja)	2003-02-04
PL353175A1 (pl)	2003-11-03
DK1194411T3 (da)	2004-10-18
BR0012328A (pt)	2007-01-02
EP1194411A1 (de)	2002-04-10
AU6688300A (en)	2001-01-30
HK1048116A1 (zh)	2003-03-21
ATE269311T1 (de)	2004-07-15
KR20020019923A (ko)	2002-03-13
HUP0201828A3 (en)	2003-02-28
HUP0201828A2 (hu)	2002-12-28
SI1194411T1 (en)	2004-10-31
CZ200212A3 (cs)	2002-04-17
CA2378595A1 (en)	2001-01-18
CN1360581A (zh)	2002-07-24
US6696446B1 (en)	2004-02-24
AU763005B2 (en)	2003-07-10
NO20020096D0 (no)	2002-01-09
SK72002A3 (en)	2002-05-09

Publication	Publication Date	Title
JP5778353B2 (ja)	2015-09-16	アゼチジン化合物、組成物及び可溶性エポキシド加水分解酵素の阻害剤としてのそれらの使用
KR100673638B1 (ko)	2007-01-23	아릴 알카노일피리다진류
JPH07508261A (ja)	1995-09-14	アレルギーおよび炎症疾患の治療用化合物
CN1129941A (zh)	1996-08-28	取代的氮杂二氢亚吲哚基化合物及其制备方法
CZ291758B6 (cs)	2003-05-14	Dihydrobenzofurany, způsob jejich výroby, jejich použití a farmaceutický prostředek
JPH08500815A (ja)	1996-01-30	化合物
US4218457A (en)	1980-08-19	2-Substituted 5-hydroxy-1H-imidazole-4-carboxamide derivatives and use
ZA200104541B (en)	2002-09-02	Benzoylpyridazines.
JP6043344B2 (ja)	2016-12-14	免疫学的障害の治療のための置換インドール誘導体
CN102307861B (zh)	2014-10-29	苯基咪唑化合物
ZA200201087B (en)	2003-07-30	Benzoylpyridazines.
KR20230052908A (ko)	2023-04-20	이중-기능성 화합물 및 이의 사용 방법
CN1578768A (zh)	2005-02-09	邻氨基苯甲酰胺及其药学应用
CN1603307A (zh)	2005-04-06	氰基丙烯酸酯衍生物及制备方法和生物活性
CA3015331C (en)	2025-09-23	5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative
FR2476646A1 (fr)	1981-08-28	Sels de n-(3-dimethyl-amino-2 - (4-pyridinyl)-2-propenylidene)-n- methylmethaniminium, leur preparation et leur utilisation comme agents cardiotoniques et comme intermediaires
JP2005501086A (ja)	2005-01-13	Ｃｏｘ−２選択的阻害剤としてのピリミジン誘導体
HK1036989A (en)	2002-01-25	Aryl alkanoylpyridazines
RU2000131707A (ru)	2003-01-27	Арилалканоилпиридазины
RU2002102246A (ru)	2003-09-10	Бензоилпиридазины
JPWO1991009847A1 (ja)	1992-01-09	エチニルフェニル誘導体、その製造法およびそれを有効成分とする循環器系疾患治療剤
KR19990085815A (ko)	1999-12-15	캐테콜 히드라존 유도체, 이의 제조방법 및 그를함유한약제학적 조성물
JPS61221177A (ja)	1986-10-01	シアノアルカンイミドアミド化合物